Keywords: DPP-4 inhibitors; GLP-1 receptor agonists; SGLT-2 inhibitors; Type 2 diabetes mellitus; cardiovascular morbidity and mortality; cardiovascular outcome studies; diabetes therapy; macrovascular complications; metformin.